Four-Course certificate Program on Cardiovascular Therapeutic Products
This unique program will instruct participants on pathways to facilitate and expedite potentially therapeutic products from conceptualization to clinical application. It is the only course in the world designed to help you move your research from the lab to market through the regulatory process!
The Cardiovascular Translational Science and Medicine program is composed of four courses: Introduction, Devices, Drugs and Biologics. Our panel of educators are international experts in cardiology, academia, industry and regulatory and reimbursement agencies. Participants will benefit from having leaders and experts in all aspects of the process of developing, testing and marketing their research.
The Devices course will be available in spring 2019. Drugs and Biologics courses will be offered in the fall of 2019 and spring of 2020. Participants can choose in which of these three pathway courses to enroll based on their interests and responsibilities. Digital badges will be awarded upon completion of each course for recognition of your accomplishments on various electronic platforms.
The office of Continuing and Professional Education is offering this fully online; asynchronous curriculum will begin in March 2018 with the required Introduction to Cardiovascular Translational Science and Medicine course.
Introduction to Cardiovascular Translational Science and Medicine
An international team of world-renowned presenters from academia, industry, the FDA and health care providers instruct participants in pathways to facilitate and expedite potentially therapeutic products from conceptualization to clinical application. This course includes modules on topics ranging from pathophysiology, statistics, clinical practice guidelines and intellectual property to 3D-printing and the role of Medicare and Medicaid in development and innovation.
- June 1, 2019.
Cardiovascular Science and Medicine Devices Course
The course is designed to improve our knowledge to enhance the implementation of translation pathways, expediting potential cardiovascular therapeutic devices from conceptualization to clinical application. This process requires 10 to 12 years — in part, because of the obligatory expertise of many distinct stakeholders who are approached sequentially as development proceeds. This contrasts to a parallel assessment in the early stage based on consultation from all of the stakeholders required to go from development to the bedside. The unique feature of this program is to bridge this gap by having all of the stakeholders participate and impart their knowledge based on their expertise and decades of experience. The educators are an international group selected from academia, industry, regulatory and reimbursement agencies. They are world renowned for their expertise in cardiovascular devices, having experience in all phases — development, pre-clinical assessment, clinical assessment, regulatory assessment, reimbursement and post-marketing evaluation. Educators for this course include: Dr. Zuckerman, director of Cardiovascular Devices (FDA), Dr. Chuck Simonton, chief medical officer for Abbott and Dr. Magdi Yacoub, world renowned for his cardiac transplantation.
- April 1, 2019.
These courses are a collaboration between the UA College of Medicine – Phoenix and the International Society for Cardiovascular Translational Research (ISCTR).
Katharine Gonzales, MEd
Graduate Training Program
College of Medicine - Phoenix
University of Arizona Continuing and Professional Education